IOVANCE BIOTHERAPEUTICS INC

We operate in the biopharmaceutical sector, which is subject to various cybersecurity risks that could adversely affect our business, financial condition, and the results of operations, including intellectual property theft, fraud, extortion, harm to employees, third party vendors or customers, violation of privacy laws and other litigation and legal risk, and reputational risk.

Risk Management and Strategy

We have designed and implemented a cybersecurity program which includes administrative, technical, and physical controls andprocesses to manage and mitigate material risks from internal and external cybersecurity threats, including but not limited to the following:

As of the date of this report, we are not aware of any material risks from cybersecurity threats, including as a result of any previous cybersecurity incidents, that have materially affected our business strategy, results of operations, or financial condition. However, as discussed under “Risk Factors” in Part I, Item 1A of this Annual Report, cybersecurity threats pose multiple risks to us, including potentially to our results of operations and financial condition. Refer to Item 1A – “Our internal computer systems, or those used by our CROs or other contractors or consultants, may fail or suffer security breaches” and “We are dependent on information technology, systems, infrastructure and data,” which are incorporated by reference into this Item 1C. As cybersecurity threats become more sophisticated and coordinated, it is reasonably likely that we will be required to expend greater resources to continue to modify and enhance our protective measures as we pursue our business strategies.

Governance:* *

The Audit Committee operates under a written charter adopted by the Company’s Board of Directors. The Audit Committee oversees, among other things, a system of internal controls, including internal controls designed to assess, identify, and manage material risks from cybersecurity threats. The Audit Committee is also responsible for the adequacy and effectiveness of the Company’s internal controls, including those internal controls that are designed to assess, identify, and manage material risks from cybersecurity threats. For further information about the Audit Committee’s role in assessing and managing the registrant’s material risks from cybersecurity threats, see “Risk Management and Strategy,” under this Item 1C.

Our team of cybersecurity professionals is led by our Vice President, Infrastructure and Security, who along with other members of the IT team collectively over extensive experience in the cybersecurity space in both the pharmaceutical and non-pharmaceutical sectors, many of whom have obtained professional security certifications. The IT team has primary responsibility for our overall cybersecurity risk management program and supervises both our internal cybersecurity personnel and our retained external cybersecurity consultants. For further information about Management’s role in assessing and managing the registrant’s material risks from cybersecurity threats, see “Risk Management and Strategy,” under this Item 1C.